A new manuscript in Nature Communications discusses the global effort to support phage therapy and features ARLG’s research along with other collaborative initiatives. “Considerations and perspectives on phage therapy from the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)” details discussions from key meetings in 2023 and 2024 where experts and regulatory authorities from the United States, Canada, the European Union, Norway, and the United Kingdom examined the scientific, regulatory, and logistical challenges surrounding phage therapy.
The publication aims to fill critical research gaps, support therapeutic research and development, and accelerate the translation of phage therapeutics into clinical practice.
This TATFAR initiative to advance phage therapy was collaborative effort among several domestic and international agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the US Food and Drug Administration (FDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), European Medicines Agency (EMA), Health Canada, and the European Commission’s Health Emergency Preparedness and Response Authority (HERA).
The insight provided by TATFAR helps to clarify the current landscape of phage therapy on a global scale and guide its direction in the future. These and other collaborative efforts inform the broader goal to advance evidence-driven approaches that will combat the threat of antimicrobial resistance worldwide.